Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
News|Articles|September 10, 2026
- Contagion, Summer 2026 Digital Edition
- Volume 11
- Issue 2
This Is the “Weight” Forward: GLP-1 Use in HIV Care
Fact checked by: Nicole Canfora Lupo
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
Advertisement
Advertisement
People living with HIV (PLWH) face a myriad of risks for comorbidities, including metabolic complications, that extend goal therapeutic outcomes well beyond just maintaining viral suppression. The intersection of HIV infection, antiretroviral therapy (ART), and metabolic disease has created unique clinical challenges that demand preemptive innovative therapeutic approaches.1 Among emerging treatment options, glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists have garnered increasing attention for their potential to address multiple metabolic complications. Although GLP-1 agonists, such as semaglutide, liraglutide, and tirzepatide (a dual GLP-1/GIP agonist), are FDA approved for several metabolic-related indications beyond adjunct diabetes mellitus treatment, such as reducing the risk of major adverse cardiovascular events and reducing further renal dysfunction for type 2 diabetes and obesity in the general population, their use in PLWH remains a promising yet evolving area of study.2,3
Related to this article
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Advertisement
Advertisement